<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2536">
  <stage>Registered</stage>
  <submitdate>20/10/2009</submitdate>
  <approvaldate>20/10/2009</approvaldate>
  <nctid>NCT00998829</nctid>
  <trial_identification>
    <studytitle>Study Evaluating The Prevalence Of Undiagnosed Psoriatic Arthritis In Patients With Plaque Psoriasis</studytitle>
    <scientifictitle>An Australian Cross-Sectional Epidemiological Study To Evaluate The Prevalence Of Undiagnosed Psoriatic Arthritis In Psoriasis Patients In Dermatology Practice Focusing On Disease Severity, Disease Burden And Quality Of Life</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>B1801063</secondaryid>
    <secondaryid>0881A6-4611</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Arthritis, Psoriatic</healthcondition>
    <healthcondition>Psoriasis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Rheumatoid arthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - questionnaire

Study population - The group comprises the entire study population


Other interventions: questionnaire
There is no therapeutic intervention in this study. However PASE (Psoriatic Arthritis Screening and Evaluation) and other patient questionnaires will be completed by participants.

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To evaluate the prevalence of undiagnosed psoriatic arthritis in patients presenting with plaque psoriasis using the PASE (Psoriatic Arthritis Screening and Evaluation) questionnaire based on a score of = 44 on the questionnaire</outcome>
      <timepoint>14 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Evaluate the positive predictive value between PASE (Psoriatic Arthritis Screening and Evaluation) score = 44 and rheumatologist-confirmed diagnosis of psoriatic arthritis in a population of tertiary Australian psoriasis patients</outcome>
      <timepoint>14 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluate the proportion of patients within the enrolled patient population with moderate-to-severe plaque psoriasis (PASI [Psoriasis Area and Severity Index] &gt; 10)</outcome>
      <timepoint>1 day</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluate the proportion of patients in a tertiary population with moderate-to-severe psoriasis with respect to treatment history and current treatment</outcome>
      <timepoint>1 day</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Describe quality of life (QoL) in a tertiary psoriasis patient population</outcome>
      <timepoint>1 day</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Explore the relationship between disease severity and QoL (quality of life) and stratified by the presence or absence of psoriatic arthritis in a tertiary population</outcome>
      <timepoint>14 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Diagnosis of plaque psoriasis

          -  &gt;= 18 years of age

          -  Able to complete English-language questionnaires</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Participation in an interventional clinical trial in previous 3 months

          -  Known rheumatologist-confirmed psoriatic arthritis</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration>Cross-sectional</duration>
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>458</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC</recruitmentstate>
    <hospital>Pfizer Investigational Site - Camperdown</hospital>
    <hospital>Pfizer Investigational Site - Darlinghurst</hospital>
    <hospital>Pfizer Investigational Site - St Leonards</hospital>
    <hospital>Pfizer Investigational Site - Westmead</hospital>
    <hospital>Pfizer Investigational Site - Carina Heights</hospital>
    <hospital>Pfizer Investigational Site - Bedford Park</hospital>
    <hospital>Pfizer Investigational Site - Box Hill</hospital>
    <hospital>Pfizer Investigational Site - Fitzroy</hospital>
    <hospital>Pfizer Investigational Site - Parkville</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>2065 - St Leonards</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>4152 - Carina Heights</postcode>
    <postcode>5042 - Bedford Park</postcode>
    <postcode>3128 - Box Hill</postcode>
    <postcode>3065 - Fitzroy</postcode>
    <postcode>3053 - Parkville</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims to collect Australian data on the prevalence of undiagnosed psoriatic
      arthritis in patients with plaque psoriasis. In addition the study will assess disease
      severity and quality of life in Australian patients with psoriasis attending specialist
      dermatology clinics.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00998829</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address>Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>